7D2A Stock Chart & Stats
€1.04
>-€0.01(-0.41%)
At close: 4:00 PM EDT
€1.04
>-€0.01(-0.41%)
Day’s Range― - ―
52-Week Range€0.67 - €1.18
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€85.61M
Enterprise Value€778.04M
Total Cash (Recent Filing)€51.79M
Total Debt (Recent Filing)€7.32M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Oct 22, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding99,336,960
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€18.45M
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low leverage provides a meaningful solvency cushion and reduces interest and refinancing pressure. This gives Sedana Medical greater financial flexibility to sustain development and commercialization efforts while addressing current losses, without the constraints associated with a heavily debt-funded balance sheet.
Strong Gross MarginA gross margin near 71% indicates substantial value remains after direct product costs, supporting attractive unit economics for the Sedaconda device-and-drug model. If revenue and adoption recover, this margin structure could provide operating leverage as commercial scale increases over the coming quarters.
Recurring ICU ConsumablesThe administration device creates repeat purchasing potential because it is used on a per-patient or limited-use basis. Combined with Sedaconda isoflurane sales, an expanding installed base of ICUs could support recurring consumables and anesthetic demand rather than relying only on one-time equipment sales.
Bears Say
Sharp Revenue ContractionA 35.2% TTM revenue decline signals weakening commercial traction and reduces the scale available to absorb fixed operating expenses. Unless growth resumes, the contraction can delay operating breakeven, limit reinvestment capacity, and make the company more dependent on external funding to pursue market expansion.
Persistent Operating LossesPersistent operating and net losses show that the business has not yet converted its product offering and high gross margin into sustainable profitability. Continued losses can constrain strategic flexibility and increase the importance of future revenue growth, cost control, and successful commercial execution.
Sustained Cash BurnNegative operating cash flow across every reported period indicates that core operations continue to consume cash rather than fund themselves. Deeply negative free cash flow raises ongoing funding needs and could force management to prioritize liquidity preservation over investment in growth and commercialization.
Sedana Medical AB News
7D2A FAQ
What was Sedana Medical AB’s price range in the past 12 months?
Sedana Medical AB lowest stock price was €0.67 and its highest was €1.18 in the past 12 months.
What is Sedana Medical AB’s market cap?
Sedana Medical AB’s market cap is €85.61M.
When is Sedana Medical AB’s upcoming earnings report date?
Sedana Medical AB’s upcoming earnings report date is Oct 22, 2026 which is in 16 days.
How were Sedana Medical AB’s earnings last quarter?
Sedana Medical AB released its earnings results on Jul 17, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of -€0.008 by -€0.001.
Is Sedana Medical AB overvalued?
According to Wall Street analysts Sedana Medical AB’s price is currently Overvalued.
Does Sedana Medical AB pay dividends?
Sedana Medical AB does not currently pay dividends.
What is Sedana Medical AB’s EPS estimate?
Sedana Medical AB’s EPS estimate is >-0.01.
How many shares outstanding does Sedana Medical AB have?
Sedana Medical AB has 99,336,960 shares outstanding.
What happened to Sedana Medical AB’s price movement after its last earnings report?
Sedana Medical AB reported an EPS of -€0.009 in its last earnings report, missing expectations of -€0.008. Following the earnings report the stock price went up 0.667%.
Which hedge fund is a major shareholder of Sedana Medical AB?
Currently, no hedge funds are holding shares in DE:7D2A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sedana Medical AB
Sedana Medical AB (publ) is a medical technology firm that engineers, promotes, and distributes healthcare devices both within Sweden and across global markets. Its product portfolio includes the Sedaconda ACD-L and Sedaconda ACD, single-use medical tools designed for delivering volatile anesthetics, alongside the Sedaconda Syringe (a 50/60ml syringe) and a Sedaconda ACD starter kit. The company also provides FlurAbsorb and FlurAbsorb-S, active carbon filtration systems engineered to collect residual anesthetic gases discharged by ventilators. Complementing these are the FlurAbsorb accessory kit, which facilitates connecting ventilator exhausts and gas monitors to the filters, and the FlurAbsorb mount, used to secure the filter during anesthetic gas removal. Further offerings encompass the AMG-06 Gas Monitor, which enables ongoing, non-invasive sidestream measurement of carbon dioxide and anesthetic levels in inhaled and exhaled breaths. Additionally, they supply the Sedaconda Filling Adapter, a disposable tool for securely and simply transferring isoflurane from its container to a Sedaconda Syringe, as well as an array of supplemental items like DRYLINE II Water Traps, the WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Lines. Established in 1999, Sedana Medical AB (publ) maintains its corporate headquarters in Danderyd, Sweden.